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Mutations in myotilin gene (MYOT) have been associated with variable syndromes including limb girdle
muscular dystrophy type 1A (LGMD1A) and a subgroup of myoﬁbrillar myopathy (MFM/MYOT). We studied
six Spanish patients from three unrelated kindreds and seven patients without family history. Three previously
reported and two novel disease-associated MYOT mutations were identiﬁed in this group of patients. The
disease is characterized by the onset at the age of 42–77 years with muscle weakness initially in distal or
proximal leg muscles, eventually spreading to other muscle groups of the lower and upper extremities.
Associated signs of cardiomyopathy, respiratory failure and peripheral neuropathy are present in a fraction
of patients. Myopathological features of focal myoﬁbrillar destruction resulting in intracytoplasmic deposits,
stronglyimmunoreactivetomyotilin,multiplerimmedandcentrallyorsubsarcolemmallylocatednon-rimmed
vacuoles and streaming Z-lines, were observed in each patient studied. The Spanish cohort, the largest group of
patients studied so far, shares phenotypic features with both LGMD1A and MFM/MYOT variants thus estab-
lishinga continuum of phenotypic manifestations characteristic of myotilinopathy, an emerging neuromuscular
disorder.
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Abbreviations:C K= creatinine kinase; EKG = electrocardiography; EMG = electromyography; IBM = inclusion body myositis;
LGMD1A = limb girdle muscular dystrophy type 1A; MFM = myoﬁbrillar myopathy; MYOT = myotilin gene; MRC = Medical
Research Council; MHC = major histocompatibilty complex; RBBB = right bundle branch block; ZASP = Z-band alternatively
spliced PDZ motif-containing protein
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Introduction
Myotilin is a 57 kDa sarcomeric Z-line associated protein
expressed strongly in skeletal muscle and weakly in cardiac
muscle (Salmikangas et al., 1999). Myotilin plays a signiﬁcant
role in sarcomere assembly by acting together with a-actinin
and ﬁlamin C to cross link actin into tightly packed bundles
(Salmikangas et al., 2003). The resulting structures support
the integrity of the contracting muscle cell (van der Ven et al.,
2000). Myotilin is encoded by a single copy gene (MYOT,
TTID) located on chromosome 5q31 (Salmikangas et al.,
1999; van der Ven et al., 2000; Yamaoka et al., 1994),
which encompasses 10 exons and codes for 498
amino acids. The gene is highly conserved among vertebrate
species.
Currently known disorders associated with mutations in
the myotilin gene (MYOT) (myotilinopathies) include auto-
somal dominant limb girdle muscular dystrophy type 1A
(LGMD1A) (Hauser et al., 2000, 2002) and a subgroup of
myoﬁbrillar myopathy (MFM) associated with myotilin
mutations (MFM/MYOT) (Selcen and Engel, 2004).
LGMD1A has so far been characterized in two families.
The patients of a large West Virginian family carrying the
myotilin Thr57Ile mutation exhibited an adult-onset prox-
imal leg weakness subsequently spreading to involve distal leg
and both proximal and distal arm muscles (Gilchrist et al.,
1988; Hauser et al., 2000). The pattern of inheritance was
autosomal dominant. Some affected individuals had a
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 distinctive nasal dysarthric pattern of speech. Myopatholo-
gical examination demonstrated variation in ﬁbre size, ﬁbre
splitting, large number of rimmed vacuoles and patches of
Z-line streaming (Gilchrist et al., 1988; Hauser et al., 2000).
Members of the second three-generation Argentinean
LGMD1A family showing a myotilin Ser55Phe mutation
developed proximal limb weakness by age 42–58 years that
later progressed to involve distal limb muscles (Hauser et al.,
2002). Two of four affected individuals had dysarthric speech.
MFM is deﬁned myopathologically as a focal dissolution of
the myoﬁbrils, accumulation of the products of myoﬁbrillar
degradation and ectopic expression of multiple proteins
(De Bleecker et al., 1996; Nakano et al., 1996). The highly
heterogeneous MFM entity includes subgroups of patients
showing mutations in desmin, aB-crystallin, selenoprotein N,
Z-band alternatively spliced PDZ motif-containing protein
(ZASP) and myotilin (Goldfarb et al., 1998; Vicart et al., 1998;
Ferreiro et al., 2004; Selcen and Engel, 2004, 2005). The
MFM/MYOT subtype was described in six unrelated patients
with Ser55Phe, Ser60Cys, Ser60Phe and Ser95Ile myotilin
mutations (Selcen and Engel, 2004). The pattern of inherit-
ance was identiﬁed as autosomal dominant in one family. The
age of disease onset varied from 53 to 77 years. Three patients
had muscle weakness in distal leg muscles and two had pre-
dominant proximal weakness. Each patient showed clinical,
EMG and histologic evidence of peripheral neuropathy on
muscle biopsies. Cardiac involvement was detected in three
patients. Granular and hyaline deposits, some of them
congophilic, and small vacuoles containing membranous
material were seen in trichrome stained sections. Strong
immunoreactivity for myotilin, dystrophin, desmin, plectin
and gelsolin was present. Streaming of the Z-line at the ultra-
structural examination was a prominent feature (Selcen and
Engel, 2004).
We report on a series of newly identiﬁed Spanish patients
with myotilinopathy showing a clinical/pathological pheno-
type that appears to be intermediate between the previously
described LGMD1A and MFM/MYOT subtypes, allowing to
establish a continuum of clinical/pathological manifestations
that deﬁne better diagnostic pattern of myotilinopathy.
Patients and methods
Patient and family ascertainment
We have identiﬁed and clinically evaluated 13 patients aged
42–77 years at the disease onset, with 6 patients originating from 3
multigenerational Spanish families (Fig. 1) and additional 7 patients
having no family history. All these individuals were a part of a group
of 22 patients (13 familial and 9 sporadic cases) who were diagnosed
as suffering from MFM based on a muscle biopsy study. Each of the
22 patients was analysed for the presence of mutations in desmin and
aB-crystallin genes; 3 of these patients showed mutations in desmin,
and no changes were found in aB-crystallin. The following invest-
igations were carried out: pedigree analysis, neurological examina-
tion, including muscle strength evaluation according to the Medical
Research Council (MRC) grading scale, serum creatinine kinase
(CK) level assessment, electrophysiological studies that consisted
of sensory (median and sural nerves) and motor (common peroneal
nerve) nerve conduction tests and concentric needle EMG (in
11 patients), cardiologic examination with electrocardiography
(EKG) and echocardiography, respiratory function tests and muscle
CT scanning at midthigh and midlower leg levels (in 7 patients).
Muscle biopsy
Open muscle biopsy was performed on 12 patients. Muscle samples
were obtained from the soleus muscle in one patient, the quadriceps
in four patients, deltoid in four patients and gastrocnemius in the
remaining three. In three patients, two muscle biopsies were neces-
sary before the diagnosis of MFM could be established. Samples were
processed for routine histochemical tests and immunocytochemical
analysis of desmin, actin, dystrophin, gelsolin, aB-crystallin, ubi-
quitin, phospho-tau and amyloid bA4 as previously described
(Olive ´ et al., 2004). Myotilin immunocytochemistry was carried
out using a mouse monoclonal anti-myotilin antibody (Novocastra,
Newcastle upon Tyne, UK) at a dilution of 1 : 150. Immunohisto-
chemical typing of the mononuclear cells and MHC class I immuno-
histochemistry was performed as described (Ferrer et al., 2004).
Amyloid-like deposits were visualized with Congo red. A sample
of biopsy tissue was processed for ultrastructural examination
using standard methods.
Single- and double-labelling
immunoﬂuorescence analysis and confocal
microscopy
Cryostatsectionswerestainedwithsaturatedsolutionof Sudanblack
B (Merck, Darmstadt, Denmark) for 30 min to block autoﬂuores-
cence of lipofuscin granules, rinsed in 70% ethanol and washed in
distilled water. The sections were incubated at 4 C overnight with
mouse monoclonal anti-myotilin antibody (Novocastra) at 1 : 150
dilutionandeitherrabbitpolyclonalanti-ubiquitin(Dako,Barcelona,
Spain) or goat anti-clusterin antibody (Chemicon, Temecula, CA)
at dilutions of 1 : 100 or 1 : 200, in a vehicle solution composed
of Tris buffer, pH 7.2, containing 15 mmol/l NaN3, and protein
(Dako). Secondary antibodies were Alexa488 anti-goat and
Alexa546 anti-mouse or anti-rabbit (all from Molecular Probes,
Eugene, OR) at 1 : 400 dilution. After washing with PBS, the sections
were incubated in a cocktail of secondary antibodies in the same
vehicle solution for 45 min at room temperature. After washing in
PBS, the sections were mounted in immuno-Fluore Mounting
medium (ICN Biomedicals, Costa Mesa, CA), sealed and dried over-
night. The sections were examined under a Leica TCS-SL confocal
microscope. Sections incubated with just one primary antibody and
the corresponding secondary antibody, and sections incubated with
the secondary antibodies alone, served as controls.
Genetic analysis
Genetic studies were approved by the Institutional Review Board of
the National Institute of Neurological Disorders and Stroke, NIH.
Genomic DNA was extracted from anticoagulated blood using the
Wizard Genomic DNA Puriﬁcation Kit (Promega) and used as
template for ampliﬁcation of MYOT exons with intronic primers
designed for this purpose (primer sequences are available on
request). Ampliﬁcation was carried out using an optimal procedure
designed for each separate segment. PCR-produced DNA was
puriﬁed using QIAquick PCR Puriﬁcation Kit (Qiagen, Valencia,
CA) and sequenced in both directions using DyeTerminator
Sequencing Protocol on an ABI 3100 DNA Analyser (Applied
2316 Brain (2005), 128, 2315–2326 M. Olive ´ et al.
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 Biosystems, Foster City, CA). In addition, 100 Spanish unrelated
control individuals were analysed for sequence variations in
exon 2 of MYOT.
Results
Analysis of gene sequences
Analysis of MYOT sequences led to the identiﬁcation of
heterozygousmissensemutationsin13patients.TheSer60Phe
mutation was detected in one sporadic patient, Ser55Phe in
three unrelated sporadic cases and in a multiplex family; the
Ser60Cys mutation was identiﬁed in one sporadic patient and
two other multiplex families. Previously unknown mutations
were identiﬁed in two patients: an A!G change in codon
36 resulting in a predicted amino acid replacement of lysine
with glutamic acid (Lys36Glu), and a C!A alteration at
codon 74 that resulted in a glutamine to lysine substitution
(Gln74Lys) (Table 1). A single unaffected Spanish individual
(a family member of a patient with desminopathy) showed a
G!A substitution at codon 115 also resulting in amino acid
replacement of threonine for alanine. All these changes were
found in the serine-rich area of MYOT that is highly
Fig. 1 Pedigrees of Families 1 and 2.
Table 1 Myotilin mutations
Protein
domain
Codon Wild-type
codon sequence
Mutant codon
sequence
Wild-type
amino acid
Mutant amino
acid
Reference
Serine-rich 36 AAA GAA Lys Glu This study
Serine-rich 55 TCC TTC Ser Phe Hauser et al., 2002
Serine-rich 57 ACA ATA Thr Ile Hauser et al., 2000
Serine-rich 60 TCT TGT Ser Cys Selcen and Engel, 2004
Serine-rich 60 TCT TTT Ser Phe Selcen and Engel, 2004
Serine-rich 74 CAG AAG Gln Lys This study
Serine-rich 95 AGC ATC Ser Ile Selcen and Engel, 2004
Myotilinopathy Brain (2005), 128, 2315–2326 2317
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 conserved through the evolution (Hauser et al., 2000). There
were no irregularities in this region on sequencing of 100
(200 chromosomes) Spanish control individuals.
Clinical features
The type of inheritance was autosomal dominant in two
families with ﬁve studied patients, whereas in the other
seven patients there was no evidence of a positive family
history in at least three generations. The remaining patient
had a brother similarly affected, but the pattern of inheritance
could not be established. Detailed clinical examination of
non-symptomatic ﬁrst-degree relatives of two sporadic
cases detected no signs of myopathy.
Family 1
Of eight members known to be affected, a father and his two
sons (II :6, III:1 and III:2, Fig. 1) showing the myotilin het-
erozygous Ser55Phe mutation were studied in detail. They
developed weakness in distal muscles of the legs at the age
of 48–50 years progressing to involve other limb muscles and
neck extensors. On examination, the father and the older son
had severe weakness and wasting of distal leg muscles and to a
lesser extend hip adductors, knee ﬂexors, iliopsoas, deltoids,
wrist and ﬁnger extensors and neck extensors (Fig. 2). Deep
tendonreﬂexeswereabsentinthelowerlimbs.Speechwasnot
affected and sensation was intact. CK levels were twice the
normal values. EKG and echocardiography examinations
were normal. EMG showed signs of myopathy with spontan-
eous activity at rest. Nerve conduction studies were normal.
The younger son had similar but milder symptoms. Other
family members presented around the age of 50 years with
weakness in the distal leg muscles eventually spreading
to other muscle groups. None had dysarthria or cardiac
involvement.
Family 2
Six members of another Spanish family suffered from muscle
weakness and cardiomyopathy. A father and daughter (II:2
and III:2, Fig. 1) carrying the Ser60Cys myotilin mutation
presented at ages 60 and 58 years with bilateral foot drop
eventually involving proximal leg muscles and the upper
limbs. Examination revealed severe weakness and wasting
of the anterior and posterior leg compartments, hip adduct-
ors, knee ﬂexors as well as wasting of deltoids, wrist and ﬁnger
extensors, more pronounced in the father. Reﬂexes were
absent or diminished throughout. Speech was not affected
and sensation was intact. At the age of 70 years, the father
was diagnosed with cardiomyopathy and died from congest-
ive cardiac failure. The daughter developed cardiomyopathy
at the age of 72 years; her echocardiographic study showed
mild hypokinesia of the right ventricle with no overt hyper-
trophy or dilatation of the heart chambers. Respiratory
function tests did not show any abnormalities. Serum CK
was within normal levels. Four other family members had
a similar disease and three died of cardiac failure.
Family 3
An 81-year-old man, carrying the Ser60Cys myotilin muta-
tion, presented at the age of 65 years with weakness in the
distal leg muscles later involving proximal muscles of lower
limbs and upper extremities. Examination revealed hyper-
nasal voice, and severe weakness and wasting of the anterior
and posterior leg muscles, iliopsoas, hip adductors, knee ﬂex-
ors as well as wasting of deltoids, wrist and ﬁnger extensors.
Reﬂexeswerehypoactivethroughout;heelcordsweretight.At
the age of 70 years, he developed restrictive respiratory insuf-
ﬁciencythat required nocturnal ventilation support. CKlevels
were at normal values. EKG showed a right bundle branch
block (RBBB). Echocardiography was normal. EMG showed
signs of myopathy with spontaneous activity at rest. Nerve
conduction studies were normal. His only brother was sim-
ilarly affected; both parents had died with no signs of
myopathy.
Sporadic cases
Of seven sporadic patients, three presented with weakness in
the distal leg muscles, two others had initial weakness in
proximal muscles of the lower limbs and one patient presen-
ted with proximal and distal leg weakness. In the advanced
phases of illness, all patients had severe weakness in distal and
proximal leg muscles, and mild to moderate weakness in
deltoids and wrist extensors. None had speech disturbances.
Deep tendon reﬂexes were absent at the ankle and knee, but
commonly preserved in the upper extremities. Tight heel
cords were noted in three patients. A 78-year-old male had
hypesthesia to all modalities; his nerve conduction studies
suggested a mild motor and sensory axonal neuropathy. At
the age of 75 years, this patient developed severe respiratory
insufﬁciency that required nocturnal ventilation support.
EKG showed a left bundle branch block in this patient.
Fig. 2 Wasting of wrist and ﬁnger extensors (A); severe atrophy
of the anterior compartment of the lower leg with normal
quadriceps bulk (B), in a member of Family 1 (older son).
2318 Brain (2005), 128, 2315–2326 M. Olive ´ et al.
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Norespiratoryinsufﬁciency,cardiomyopathyorsignsofneuro-
pathy were observed in other patients in this group. CK level
was normal or slightly elevated. Needle EMG showed signs of
myopathy with spontaneous activity at rest. The remaining
patient presented at the age of 42 years with dyspnea on
exertion, later progressing to severe respiratory insufﬁciency.
The patient also developed distinct nasal voice and mild mus-
cle weakness in iliopsoas, knee ﬂexors, hip adductors, wrists
Fig. 3 Muscle CT scan images of four myotilinopathy patients at midthigh (A, C, E and G) and midlower leg (B, D, F and H) levels. In
patients with initial distal leg weakness (A, B, C and D) changes are seen in the soleus (B), followed by changes in medial gastrocnemius,
anterior tibialis, extensor digitorum and extensor hallucis longus as well as in the peroneal group (D). Areas of mildly decreased attenuation
are also present in the hip adductors, and in the semimebranosus (C). In a patient with initial proximal muscle weakness, atrophy is found in
the hip adductors, biceps femoris, semimebranosus and sartorius (E), with no obvious changes in the muscles of the calf (F). In a patient with
both proximal and distal muscle weakness at the disease onset, areas of decreased attenuation are observed in the hip adductors, biceps
femoris, semimebranosus and in the vastus medialis (G), as well as in the soleus and medial gastrocnemius muscles (H). A, B: Family 1,
younger son; C, D: Family 1, older son; E, F: sporadic case, Gln74Lys mutation; G, H: sporadic case, Ser55Phe mutation.
Myotilinopathy Brain (2005), 128, 2315–2326 2319
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 Fig. 4 Histochemical ﬁndings in myotilinopathy patients. (A) Variation in the ﬁbre size, increased numbers of internal nuclei, abnormal
inclusions in the cytoplasm or under the sarcolemma; a large rimmed vacuole is seen in an atrophic ﬁbre. (B) Giant ﬁbre containing hyaline
deposits and multiple vacuoles. (C) Several rimmed vacuoles in a single ﬁbre. (D) Rimmed and non-rimmed vacuoles and eosinophilic
inclusions in a muscle ﬁbre; an adjacent small ﬁbre also contains non-rimmed vacuoles. (E) Mononuclear cells invading an apparently normal
ﬁbre. (F) Muscle ﬁbre necrosis with phagocytosis and small regenerating ﬁbres. A hyaline inclusion in the adjacent ﬁbre. (G) Several
abnormal ﬁbres containing blue–red amorphous inclusions and vacuoles. (H) A small cluster or cytoplasmic bodies (top), and a serpentine
hyaline structure (bottom). (I) Group of ﬁbres bearing hyaline inclusions and small red spheroid bodies. (J) Well delimited areas lacking
oxidative enzyme activity. (K) Strong PAS positivity. (L) PAS positivity removed by diastase digestion. A–F: H and E; G–I: modiﬁed
trichrome; J: NADH; K: PAS stain; L: PAS-diastase. A, C, F, H: Family 1, younger son; B, D, E, J–L: sporadic case with Ser60Cys mutation;
G: Family 2, father; I: sporadic case with Ser60Cys mutation. Bar in A = 25 mm; B–L, bar in L = 25 mm.
2320 Brain (2005), 128, 2315–2326 M. Olive ´ et al.
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 and ﬁnger extensors. In addition, there was weakness and
atrophy of pectoralis and sternocleidomastoid muscles.
EKG showed an RBBB. Echocardiographic study was normal.
The disease progressed very slowly; 4 of 12 patients became
wheelchair-dependent 10–20 years after the disease onset.
CT-scan studies
In patients with initial distal leg weakness, muscle CT scans at
the midcalf level showed fatty replacement in soleus and
medial gastrocnemius muscles followed by anterior tibialis
and peroneal group, and mild involvement of the hip adduct-
ors (Fig. 3). In cases with proximal onset, muscle hypodensity
was noted in the hip adductors, biceps femoris, semimem-
branosus and sartorius with no obvious changes in the calf
muscles. Finally, in the patient with both proximal and distal
initial muscle weakness, marked decrease of attenuation was
observed inmedialgastrocnemious,soleus,hipadductorsand
biceps femoris. In advanced illness, all muscles of the anterior
and posterior compartments of the legs were completely
replaced by fatty tissue, irrespective of the mode of presenta-
tion. The quadriceps muscles, especially rectus femoris and
vastus lateralis, were relatively well preserved.
Histologic features
Muscle biopsy in 11 affected individuals showed marked vari-
ation in ﬁbre size and increased number of internal nuclei.
Atrophic rounded ﬁbres of either histochemical type often
clusteredinsmallgroups (Fig.4A).Polymorphicinclusionsof
varying size and shape (Fig. 4A, B, D, G–I) were seen in
multiple muscle ﬁbres of 11 patients. These inclusions appear
as non-hyaline irregular patches located in the centre of the
ﬁbre or in the subsarcolemmal space (Fig. 4A). They appear
pink with HE and dark-blue with the modiﬁed trichrome
Gomori stain. Single or multiple hyaline inclusions staining
bright pink with HE (Fig. 4B and D) and blue–red or
red–purple with the modiﬁed trichrome Gomori stain
Fig. 5 Serial consecutive sections stained with modiﬁed trichrome (A), and immunocytochemically reacted with myotilin (B), ubiquitin
(C), desmin (D), aB-crystallin (E) and dystrophin (F) at a hyaline lesion (sporadic case with Lys36Glu mutation). Serial sections stained with
H and E (G), and immunostained with desmin (H) and gelsolin (I) at subsarcolemmal non-hyaline lesions (Family 1, younger son).
Bar in I = 25 mm.
Myotilinopathy Brain (2005), 128, 2315–2326 2321
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 (Fig. 4G–I) were also observed; they varied in shape and size
and lacked oxidative (Fig. 4J) and ATPase activity. Some
hyaline structures were congophilic.
Large numbers of lobulated ﬁbres on oxidative stains and
ﬁbre type grouping were noted in a single patient. Cytoplas-
mic bodies were seen in most cases (Fig. 4H and I). Single or
multiple vacuoles rimmed by basophilic membranous mater-
ial (Fig. 4A and C) were observed in each patient studied.
Large numbers of non-rimmed vacuoles (Fig. 4B, D, G and I)
were observed in nine cases. The non-rimmed vacuoles
appeared as empty spaces located under the sarcolemma or
in the cytoplasm. Some of them showed strong PAS-positivity
that disappeared after diastase digestion (Fig. 4K and L).
Strong acid phosphatase activity was noted in some ﬁbres.
Foci of mononuclear inﬂammatory cells (Fig. 4E and F),
mainly composed of CD8+T cells invading necrotic and
non-necrotic ﬁbres were prominent in four cases. Sarco-
lemmal expression of MHC class I antigens was not
observed. The morphological abnormalities tended to be
restricted to certain areas of the biopsy specimen and no
abnormality was observed in muscles showing no signs of
weakness.
Immunohistochemical studies showed strong immuno-
reactivity for myotilin, desmin, aB-crystallin, ubiquitin,
phospho-tau, dystrophin, actin, gelsolin, amyloid bA4 in
the abnormal ﬁbres of each studied patient (Fig. 5A–I).
Under confocal microscopy, myotilin deposits appeared as
conﬂuent patches covering signiﬁcant parts of the muscle
ﬁbre or as multiple aggregates scattered in the cytoplasm
or subsarcolemmal spaces. Atrophic ﬁbres displayed diffuse
myotilin immunoreactivity (Figs 6 and 7). Myotilin largely
co-localized with ubiquitin (Fig. 6) and clusterin (Fig. 7) as
revealed by double-labelling immunoﬂuorescence.
On electron microscopy, streaming of the Z-line and focal
dissolution of myoﬁbrils was noted in each studied case.
Electron-dense structures corresponding to the remnants of
the Z-lines were always present. Large numbers of autophagic
vacuoles and myelin-like structures were present in each case
studied (Fig. 8). In addition, affected ﬁbres contained large
amounts of granular material and free glycogen.
Fig. 6 Double-labelling immunoﬂuorescence reactions with ubiquitin (green, A, D) and myotilin (red, B, E) in abnormal muscle ﬁbres. Note
that ubiquitin and myotilin deposits do not always exactly co-localize (merge yellow, C, F) (Family 2, daughter). Sections immunostained
with secondary antibodies alone served as negative controls (G, H and I).
2322 Brain (2005), 128, 2315–2326 M. Olive ´ et al.
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 Discussion
Thirteen newly identiﬁed patients showing mutations in the
myotilin gene were studied and the results compared with
previous reports describing two other groups of patients with
myotilinopathy (Table 2). The pattern of inheritance was
autosomal dominant in LGMD 1A, but some patients of
the MFM/MYOT group and our group did not have family
history of disease. The age of disease onset in our patients
(42–77 years) is overlapping with both LGMD1A and
MFM/MYOT cohorts. The rate of disease progression was
very slow, taking >10 years before the patients became dis-
abled. Distal muscle weakness of the lower limbs was the
presenting symptom in 10 patients, whereas proximal leg
weakness was the initial complaint in 2. A similar ratio was
observed in the MFM/MYOT group (Selcen and Engel, 2004),
but all LGMD1A patients had proximal leg weakness
(Gilchrist et al., 1988). In a single patient, respiratory insuf-
ﬁciency was the ﬁrst manifestation of the disease. With the
progression of illness, all limb muscles were affected in each
group of patients leading to quadriparesis at an advanced
stage. In the majority of our patients, foot drop owing to
anterior tibialis weakness was the ﬁrst symptom; however,
CT-scan studies performed early in the course of illness sug-
gested that the disease actually started in the posterior lower
leg muscles with no signiﬁcant functional consequences until
the anterior group became weak. As the disease progressed,
iliopsoas, knee ﬂexors and hip adductors became weak. In
patients with distal weakness at the onset, involvement of the
upper extremities occurred 5–7 years after the disease onset.
Wrist andﬁnger extensorsand deltoids werethe mostaffected
muscles. Weakness of neck extensors was noted in some
patients of either group. Facial muscles were affected in 3 of
16 patients of the LGMD1A original family, but have not
been seen in other groups. In a single patient with the
Gln74Lys mutation pectoralis muscles were affected.
Some patients in both LGMD1A families had dysarthric
speech, whereas the MFM/MYOT did not have dysarthria and
only two of the patients we studied had hypernasal voice.
Deep tendon reﬂexes were decreased at the ankles in patients
of either group, but in most cases were present in the arms.
The tightness of Achilles tendons, a characteristic feature in
the LGMD1A families, was rarely present in the MFM/MYOT
Fig. 7 Double-labelling immunoﬂuorescence reactions with clusterin (green, A, D) and myotilin (red, B, E) in abnormal muscle
ﬁbres. Note the co-localization of clusterin and myotilin (merge yellow, C, F) (sporadic case with Ser60Cys mutation). Sections
immunostained with the secondary antibodies alone served as negative controls (G, H and I).
Myotilinopathy Brain (2005), 128, 2315–2326 2323
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 group but seen in four of our patients. Peripheral neuropathy
was a uniform feature the MFM/MYOT group; in view of this
fact,weperformed motorandsensory nerveconductionstud-
ies which were normal in each patient studied, except for a
singlepatientwithdistalhypesthesiawhoshowedasymmetric
motor and sensory axonal polyneuropathy. Peripheral neuro-
pathy was also absent in patients with the LGMD1A pheno-
type (Gilchrist et al., 1988).
Signs of cardiomyopathy were present in the members
of the Ser60Cys family, and EKG abnormalities without
advanced heart block or cardiac dysfunction were observed
in three unrelated patients. Cardiac involvement has previ-
ously been reported in three MFM/MYOT patients but not in
patients with the LGMD1A phenotype. It has been suggested
that the absence of cardiac dysfunction in LGMD1A patients
could be related to the younger age of these patients at the
time of examination (Selcen and Engel, 2004), however some
of our patients were examined at the age of 78–82 years and
showed no evidence of cardiomyopathy. These observations
suggest that involvement of cardiac muscle is not a constant
feature of myotilinopathy. Three patients in our group
developed restrictive respiratory failure with severely reduced
forced vital capacity necessitating nocturnal ventilatory
support. This is the ﬁrst report of respiratory insufﬁciency
in patients with myotilinopathy.
Histologic characteristics make an especially strong con-
tribution to the phenotypic deﬁnitions of myotilinopathy.
Hyaline and non-hyaline lesions were observed in the
majority of the patients we studied and the patients of the
MFM/MYOT group (Selcen and Engel, 2004), but were not
reported in the LGMD1A patients. Rimmed vacuoles corres-
ponding to the autophagic vesicles observed under EM were
present in patients of each group. In addition to the rimmed
vacuoles, single or multiple non-rimmed vacuoles were also
observed.Thesevacuolatedareasrepresentfociofmyoﬁbrillar
destruction containing remnants of degraded myoﬁbrillar
structures, membranous material and glycogen granules;
therefore, they should be viewed as cytoplasmic spaces rather
than true vacuoles. The striking vacuolar changes are
important clues strongly indicating myotilinopathy. Z-line
irregularity found in each group is another unifying
feature of myotilinopathy. We observed focal inﬂammatory
changes in four patients and similar changes were previously
described in a single MFM/MYOT patient. Abnormal protein
deposits found in our group of patients were similar to those
reported in patients with other types of MFM (De Bleecker
et al., 1996; Olive ´ et al., 2004; Ferrer et al., 2004; Selcen
et al., 2004).
The causesand mechanismsof protein aggregation in myo-
tilinopathy patients remain unknown. We recently suggested
that impaired proteasomal expression may explain in part the
abnormal protein accumulation (Ferrer et al., 2004). In the
present study, clusterin depositions co-localizing with myo-
tilin aggregates were found in many abnormal ﬁbres.
Fig. 8 Ultrastructural aspect showing streaming Z-lines (A), areas of myoﬁbrillar destruction containing remnants of myoﬁbrils (B),
electron-dense material of Z-line origin (C), and large autophagic vacuoles (D). Bar = 1 mm.
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 Clusterin (Apolipoprotein J, SP40,40), a syaloglycoprotein
with a nearly ubiquitous tissue distribution (Jones et al.,
2002), is found as a component of abnormal protein accu-
mulation in several neurodegenerative diseases including bA-
amyloid plaques in Alzheimer’s disease (McGeer et al., 1992;
Lidstro ¨m et al., 1998), prionopathies (Sasaki et al., 2002a;
Freixes et al., 2004) and a-synucleinopathies (Sasaki et al.,
2002b). The results of the present study suggest that clusterin
participates in protein aggregation occurring in myotilino-
pathy patients. Clusterin expression and the aggresome in
MFMs and other myopathic conditions are analysed in detail
elsewhere (Ferrer et al., 2005).
Inﬂammatory changes in late onset distal myopathy with
mild or no CK elevation, myopathic EMG with prominent
spontaneous activity, rimmed vacuoles and protein deposits
inmuscleﬁbresmaybeconfusedwithinclusionbodymyositis
(IBM). Early involvement of quadriceps and ﬁnger ﬂexors
in IBM, which are relatively spared in myotilinopathies, are
important clinical clues for the diagnosis. Furthermore, in
contrast to IBM, the expression of MHC class I antigens in
the cytoplasmic membrane is not observed.
Oftheentiregroupof22patientswehadtheopportunityto
study, the pathologic features of 13 myotilinopathy patients
differed from those in 3 patients with desminopathy and
6 genetically unidentiﬁed patients in several respects:
(i) The myoﬁbrillarlesions observed in desminopathy cases
and genetically unidentiﬁed cases were less abundant,
less ﬂorid and mainly observed as discrete plaque-like
inclusions compared with irregular polymorphous
inclusions observed in myotilinopathy.
(ii) Vacuolar changes were much more prominent in
myotilinopathy patients.
(iii) The granuloﬁlamentous material typically observed in
desminopathies at the ultrastructural level was not
observed in cases of myotilinopathy.
Table 2 Phenotypic characteristics of myotilinopathies
LGMD1A original
family*
LGMD1A second
family
†
MFM/MYOT familial
and sporadic patients
‡
Present study
Phenotypic features
Number of studied patients 16 4 6 13
Myotilin mutation Thr57Ile Ser55Phe Ser55Phe, Ser60Cys,
Ser60Phe, Ser95Ile
Lys36Glu,Ser55Phe, Ser60Cys,
Ser60Phe, Gln74Lys
Pattern of inheritance AD AD AD, sporadic AD, sporadic
Onset age 18–35 42–58 50–77 42–77
Rate of progression Slow Slow Slow Slow
Clinical features
Dysarthria, nasal voice 4/16 2/4 0/5 2/13
Muscle weakness at onset PLL in 13, PUL in 11 PLL, PUL DLL, PLL DLL, PLL, respiratory muscles in 1
Weakness in additional muscle
groups found at exam
neck in 11, DLL in 11,
DUL in 4, facial in 3
DLL, DUL DUL PUL, DUL; neck in 3, pectoralis
and sternocleidomastoid in 1
Muscle atrophy No Not reported 2/5 7/13
Peripheral neuropathy No Not reported 6/6 1/13
Cardiomyopathy 0/16 Not reported 3/5 2/13
Respiratory insufﬁciency 0/16 Not reported 0/5 3/13
Muscle stiffness, myalgia 0/16 Not reported 1/6 4/13
Decreased ankle reﬂexes 16/16 Not reported 4/5 12/13
Decreased reﬂexes in the arms 5/16 Not reported 1/5 5/13
Heel cord contracture 10/16 Not reported 1/5 4/13
Creatine kinase level 1.6–9-fold increase
in 15/16
5–15-fold
increase in 4/4
Normal in 3/6; 2-fold
increase in 3/6
Normal in 9/13; 2-fold increase
in 3/13 4-fold increase in 1/13
EMG Myopathic Not reported Myopathic in 1/6;
myopathic and
neurogenic in 4/5
Myopathic in 10/11, myopathic
and neurogenic in 1/11
Nerve conduction Normal Not reported Not reported Normal in 10/11 abnormal in 1/11
Myopathology
Atrophic ﬁbres 3/8 Not reported 4/6 9/12
Fibre grouping No Not reported 2/6 1/12
Non-hyaline deposits Not reported Not reported 6/6 11/12
Hyaline deposits Not reported Not reported 6/6 11/12
Rimmed vacuoles Yes Not reported 6/6 12/12
Non-rimmed vacuoles No Not reported No 9/12
EM: Z-line streaming Yes Not reported 6/6 12/12
Autophagic vacuoles Yes Not reported 6/6 12/12
PLL,proximallowerlimb;DLL,distallowerlimb;PUL,proximalupperlimb;DUL,distalupperlimb.*Hauseretal.,2000;
†Hauseretal.,2002;
‡Selcen and Engel, 2004.
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 Accumulating data suggest that myotilinopathy constitutes
 10% of MFM patients investigated in large multinational
centres(SelcenandEngel,2004;LevG.Goldfarb,unpublished
data). The frequency of myotilinopathy among patients with
MFM in Spain may be much higher. The reasons for the high
frequency of myotilinopathy in the Spanish population are
under investigation.
Inconclusion, our clinical andmyopathologicaldata deﬁne
more precisely the myotilinopathy phenotype. Although the
initial weakness could be in distal or proximal lower limb
muscles, cardiomyopathy and respiratory insufﬁciency may
be present or absent, the overall clinical and pathological
spectrum is recognizable. The phenotypic features of the
group of patients described in this report overlap with pre-
viously characterized LGMD1A and MFM/MYOT groups.
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